As a result of high-rate tumor mutations, neoantigens are formed, which correspond to altered tumor protein sequences that have not yet been recognized by the immune system.

Since these mutations are absent from the normal human genome, the resultant tumor-specific neoantigens (TSNA) can be used as unique identifiers or markers of a specific tumor and pose exciting opportunities in immuno-oncology and vaccine therapies.

The neoantigen strategy may also apply to other diseases which rely on personalized medicines.


See our offer

QC Controls & Standards for biopharmaceuticals & API's

Our high-quality controlled peptides make a perfect fit as calibration standards for LC-MS/MS and 2D electrophoresis, for analyzing performance of mass spectrometers, and for characterizing proteins including their enzymatic activity.


Do you need a solid partner for your Peptide-based project?

Contact us